StocksFundsScreenerSectorsWatchlists
TMO

TMO - Thermo Fisher Scientific Inc Stock Price, Fair Value and News

544.98USD+3.46 (+0.64%)Market Closed

Market Summary

TMO
USD544.98+3.46
Market Closed
0.64%

TMO Alerts

  • 2 major insider sales recently.

TMO Stock Price

View Fullscreen

TMO RSI Chart

TMO Valuation

Market Cap

207.8B

Price/Earnings (Trailing)

34.9

Price/Sales (Trailing)

4.85

EV/EBITDA

26.43

Price/Free Cashflow

30

TMO Price/Sales (Trailing)

TMO Profitability

EBT Margin

14.70%

Return on Equity

12.74%

Return on Assets

6.03%

Free Cashflow Yield

3.33%

TMO Fundamentals

TMO Revenue

Revenue (TTM)

42.9B

Rev. Growth (Yr)

-4.93%

Rev. Growth (Qtr)

2.95%

TMO Earnings

Earnings (TTM)

6.0B

Earnings Growth (Yr)

2.03%

Earnings Growth (Qtr)

-5.25%

Breaking Down TMO Revenue

Last 7 days

-3.6%

Last 30 days

-6.0%

Last 90 days

-1.2%

Trailing 12 Months

-3.7%

How does TMO drawdown profile look like?

TMO Financial Health

Current Ratio

1.75

Debt/Equity

0.67

Debt/Cashflow

0.27

TMO Investor Care

Dividend Yield

0.26%

Dividend/Share (TTM)

1.4

Buy Backs (1Y)

1.07%

Diluted EPS (TTM)

15.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202343.8B43.5B43.4B42.9B
202241.1B42.8B44.2B44.9B
202135.9B38.3B39.1B39.2B
202025.6B26.2B28.5B32.2B
201924.6B24.9B25.2B25.5B
201822.0B23.1B23.9B24.4B
201718.7B19.2B19.8B20.9B
201617.3B17.6B18.0B18.3B
201516.9B16.9B16.8B17.0B
201413.8B14.9B15.9B16.9B
201312.6B12.8B12.9B13.1B
201211.9B12.2B12.3B12.5B
201110.5B10.8B11.1B11.6B
201010.3B10.4B10.5B10.4B
200910.0B9.7B9.6B9.9B
200809.9B10.1B10.3B
20070009.7B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Thermo Fisher Scientific Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 25, 2024
holmes joseph r.
acquired
-
-
46.00
vp & chief accounting officer
Mar 13, 2024
casper marc n
acquired
1,905,900
190
10,000
chairman & ceo
Mar 13, 2024
casper marc n
sold
-5,945,760
594
-10,000
chairman & ceo
Mar 12, 2024
britt lisa p.
acquired
2,852,540
198
14,345
sr. vp and chief hr officer
Mar 12, 2024
britt lisa p.
sold
-8,591,220
598
-14,345
sr. vp and chief hr officer
Mar 12, 2024
casper marc n
sold
-5,979,760
597
-10,000
chairman & ceo
Mar 12, 2024
casper marc n
acquired
1,905,900
190
10,000
chairman & ceo
Mar 11, 2024
casper marc n
acquired
1,905,900
190
10,000
chairman & ceo
Mar 11, 2024
casper marc n
sold
-5,953,600
595
-10,000
chairman & ceo
Mar 11, 2024
casper marc n
gifted
-
-
-2,000
chairman & ceo

1–10 of 50

Which funds bought or sold TMO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
Raub Brock Capital Management LP
unchanged
-
30,252
348,726
0.07%
Apr 18, 2024
Dash Acquisitions Inc.
added
3.93
641,415
14,694,300
4.64%
Apr 18, 2024
STEWART & PATTEN CO LLC
unchanged
-
21,932
252,826
0.04%
Apr 18, 2024
SeaCrest Wealth Management, LLC
added
2.48
103,916
961,321
0.12%
Apr 18, 2024
Claro Advisors LLC
new
-
344,675
344,675
0.06%
Apr 18, 2024
MEAG MUNICH ERGO, Kapitalanlagegesellschaft mbH
reduced
-2.31
911,113
13,978,100
0.51%
Apr 18, 2024
CULLINAN ASSOCIATES INC
unchanged
-
115,966
1,336,780
0.07%
Apr 18, 2024
Allspring Global Investments Holdings, LLC
added
40.46
25,529,100
72,979,600
0.11%
Apr 18, 2024
Well Done, LLC
new
-
244,109
244,109
0.05%
Apr 18, 2024
Piscataqua Savings Bank
added
14.71
4,621
22,666
0.02%

1–10 of 50

Are Funds Buying or Selling TMO?

Are funds buying TMO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TMO
No. of Funds

Unveiling Thermo Fisher Scientific Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.54%
32,977,462
SC 13G/A
Feb 08, 2024
blackrock inc.
-
0
SC 13G/A
Feb 08, 2024
blackrock inc.
7.3%
28,329,861
SC 13G/A
Feb 09, 2023
vanguard group inc
8.30%
32,534,676
SC 13G/A
Feb 03, 2023
blackrock inc.
7.9%
30,790,122
SC 13G/A
Feb 10, 2022
vanguard group inc
7.89%
31,103,788
SC 13G/A
Feb 01, 2022
blackrock inc.
7.9%
30,982,611
SC 13G
Feb 10, 2021
vanguard group inc
7.82%
30,997,381
SC 13G/A
Feb 01, 2021
blackrock inc.
7.4%
29,504,221
SC 13G/A
Feb 12, 2020
vanguard group inc
7.77%
31,187,697
SC 13G/A

Recent SEC filings of Thermo Fisher Scientific Inc

View All Filings
Date Filed Form Type Document
Apr 09, 2024
ARS
ARS
Apr 09, 2024
DEF 14A
DEF 14A
Apr 09, 2024
DEFA14A
DEFA14A
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 14, 2024
3/A
Insider Trading
Mar 14, 2024
4
Insider Trading

Peers (Alternatives to Thermo Fisher Scientific Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
174.2B
23.9B
-6.45% -5.19%
36.72
7.29
-10.33% -33.23%
39.6B
3.7B
-10.02% -2.89%
46.84
10.81
8.72% 24.44%
38.9B
6.7B
-9.88% -2.07%
31.47
5.78
-2.81% -6.58%
14.2B
9.3B
0.58% -10.70%
16.65
1.54
-6.38% -9.73%
11.6B
4.1B
-15.49% 14.49%
24.52
2.82
3.86% -2.39%
11.4B
1.9B
-6.78% 97.59%
40.46
6.07
29.17% 15.26%
11.1B
2.5B
-2.68% -8.07%
-54.22
4.43
19.93% 67.26%
10.3B
1.1B
-8.21% 57.21%
-23.68
9.51
31.99% 20.63%
MID-CAP
2.5B
929.2M
-25.64% -30.20%
1.6K
2.7
28.93% 111.61%
2.0B
563.9M
-10.26% -34.59%
-4.08
3.47
25.45% 26.76%
SMALL-CAP
430.8M
280.3M
-16.97% -3.59%
-2.26
1.54
-12.89% -148.37%
88.7M
31.2M
5.04% -86.38%
-1
2.84
5.03% -1.81%
43.1M
9.2M
0.29% -35.85%
-2.58
4.71
11.85% 44.12%
5.8M
9.0M
-32.00% -67.31%
-0.8
0.64
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Thermo Fisher Scientific Inc News

Latest updates
Defense World10 hours ago
Yahoo Finance15 Apr 202404:58 pm

Thermo Fisher Scientific Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue3.0%10,88610,57410,68710,71011,45010,67710,97011,81810,7029,3309,2739,90610,5508,5216,9176,2306,8296,2726,3166,1256,507
Costs and Expenses3.7%9,0328,7109,1099,1479,5898,9678,9698,9978,1647,0527,1106,8577,4796,0955,5265,3245,5975,3264,8205,2055,359
  S&GA Expenses4.1%2,1322,0492,1452,1192,2992,2082,2092,2772,2782,0041,8991,8262,0771,5921,7101,5511,5121,5391,5651,5281,510
  R&D Expenses2.5%327319345346391351365364392351343320376296264245262247246248251
EBITDA Margin2.5%0.20*0.20*0.19*0.19*0.21*0.21*0.23*0.24*0.26*0.29*0.29*0.29*0.26*0.23*0.19*0.21*0.21*0.21*0.21*--
Interest Expenses8.6%390359326300269173148136161128122125146144137126142164181189-
Income Taxes150.9%13353.0052.0046.0017331.0019830120327121941639431997.0040.0036.0062.002742.00114
Earnings Before Taxes-1.4%1,7401,7651,4301,3631,7771,6011,9172,5401,8622,1772,0492,7532,8972,2521,2538281,0408221,3938171,012
EBT Margin0.7%0.15*0.15*0.14*0.15*0.17*0.18*0.20*0.21*0.23*0.25*0.26*0.26*0.22*0.19*0.15*0.16*0.16*0.16*0.16*--
Net Income-5.3%1,6061,6951,3621,2921,5741,4981,6682,2201,6591,9031,8292,3372,5001,9331,1567881,0027601,119815898
Net Income Margin1.9%0.14*0.14*0.13*0.14*0.15*0.16*0.17*0.19*0.20*0.22*0.22*0.22*0.20*0.17*0.14*0.14*0.14*0.14*0.14*--
Free Cashflow59.4%3,3182,0821,2562712,9371,3901,0221,5621,6262,1261,6871,3502,7532,3421,6171031,6249011,074--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.7%98,72697,05794,10594,65897,15490,53690,57992,74795,12373,60067,69865,93169,05264,06161,59358,68858,38156,72957,97055,59656,232
  Current Assets6.5%24,58923,09219,99520,20925,22919,29918,10018,77620,11324,72419,26017,68521,95718,23415,77512,73811,89310,51411,2239,93910,625
    Cash Equivalents31.3%8,0776,1513,1333,4828,5242,9341,9052,7794,49112,0487,0355,60310,3367,5705,8373,0102,4221,3052,3141,1282,117
  Inventory-5.8%5,0885,4045,6555,6645,6345,7225,6685,4835,0514,9064,6254,3424,0293,8293,6483,4543,3703,3083,2093,1243,005
  Net PPE3.1%9,4489,1679,2929,3549,2808,6288,5298,4488,3337,0496,5606,1335,9125,1804,8874,7364,7494,4204,3944,1924,165
  Goodwill1.0%44,02043,58343,27343,14041,19640,48841,06641,72141,92426,90926,90426,82326,04125,78225,70025,61425,71425,62425,75725,23625,347
  Current Liabilities-1.0%14,01214,15814,11215,88417,01011,11810,99712,07013,4367,7536,9256,99510,3046,2286,0135,5006,1975,8447,5095,8986,147
  Long Term Debt2.7%31,30830,48929,19429,13528,90928,15029,25031,38932,33321,68818,77318,64119,10721,09120,63819,23117,07616,39216,66316,81217,719
    LT Debt, Non Current-----------18,77318,64119,10721,09120,63819,23117,07616,392--17,719
Shareholder's Equity3.1%46,73545,32843,80242,31043,97843,60842,35441,01840,85538,75736,90135,06834,51731,82429,87528,55929,68429,35528,72927,69327,594
  Retained Earnings3.3%47,36445,86944,28943,06441,91040,45239,07437,52835,43133,87632,07630,35028,11625,70523,86022,79122,09221,16520,48219,43918,696
  Additional Paid-In Capital0.7%17,28617,16517,03016,88916,74316,59616,46716,29216,17415,96015,82615,68415,57915,46715,33415,18615,06414,96414,88714,77114,621
Shares Outstanding0%386386386386392392392392394394393394396396395397400400400--
Minority Interest-161.1%-11.0018.0050.0053.0054.0059.0061.0062.0062.00---10.00--------
Float---201,177---214,582---201,672---138,640---117,442--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations54.2%3,7232,4141,5407293,4871,9371,5282,2022,4572,6502,2271,9783,3392,7081,8863561,9131,1171,2946491,801
  Share Based Compensation-9.0%61.0067.0074.0076.0075.0077.0077.0078.0077.0051.0051.0051.0051.0052.0047.0046.0043.0042.0052.0044.0044.00
Cashflow From Investing68.2%-376-1,181-443-3,142-525-545-419-670-18,692-616-626-1,998-626-365-259-260-339-198-769-181-721
Cashflow From Financing-177.0%-1,4281,855-1,456-2,5932,391-151-1,905-3,1458,4673,040-76.00-4,850-49.00-7911,180619-514-1,869690-1,425-13.00
  Dividend Payments0.7%13613513511711711811710310310210387.0087.0087.0087.0076.0076.0077.0076.0068.0068.00
  Buy Backs----3,0001,000--2,000---2,000---1,500750--750250

TMO Income Statement

2023-12-31
Consolidated Statement of Income - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues   
Revenues$ 42,857$ 44,915$ 39,211
Costs and operating expenses:   
Selling, general and administrative expenses8,4458,9938,007
Research and development expenses1,3371,4711,406
Restructuring and other costs459114197
Total costs and operating expenses35,99836,52229,183
Operating income6,8598,39310,028
Interest income87927243
Interest expense(1,375)(726)(536)
Other income/(expense)(65)(104)(694)
Income before income taxes6,2987,8358,841
Provision for income taxes(284)(703)(1,109)
Equity in earnings/(losses) of unconsolidated entities(59)(172)(4)
Net income5,9556,9607,728
Less: net (losses) income attributable to noncontrolling interests and redeemable noncontrolling interest(40)103
Net income attributable to Thermo Fisher Scientific Inc.$ 5,995$ 6,950$ 7,725
Earnings per share attributable to Thermo Fisher Scientific Inc.   
Basic (in dollars per share)$ 15.52$ 17.75$ 19.62
Diluted (in dollars per share)$ 15.45$ 17.63$ 19.46
Weighted average shares   
Basic (in shares)386392394
Diluted (in shares)388394397
Product revenues   
Revenues   
Revenues$ 25,243$ 28,548$ 30,361
Costs and operating expenses:   
Cost of revenues13,16814,24713,594
Service revenues   
Revenues   
Revenues17,61416,3678,850
Costs and operating expenses:   
Cost of revenues$ 12,589$ 11,697$ 5,979

TMO Balance Sheet

2023-12-31
Consolidated Balance Sheet - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 8,077$ 8,524
Accounts receivable, less allowances of $193 and $1898,2218,115
Inventories5,0885,634
Contract assets, net1,4431,312
Other current assets1,7601,644
Total current assets24,58925,229
Property, plant and equipment, net9,4489,280
Acquisition-related intangible assets, net16,67017,442
Other assets3,9994,007
Goodwill44,02041,196
Total assets98,72697,154
Current liabilities:  
Short-term obligations and current maturities of long-term obligations3,6095,579
Accounts payable2,8723,381
Accrued payroll and employee benefits1,5962,095
Contract liabilities2,6892,601
Other accrued expenses3,2463,354
Total current liabilities14,01217,010
Deferred income taxes1,9222,849
Other long-term liabilities4,6424,238
Long-term obligations31,30828,909
Commitments and Contingencies
Redeemable noncontrolling interest118116
Thermo Fisher Scientific Inc. shareholders’ equity:  
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 442,188,634 and 440,668,112 shares issued442441
Capital in excess of par value17,28616,743
Retained earnings47,36441,910
Treasury stock at cost, 55,541,290 and 50,157,275 shares(15,133)(12,017)
Accumulated other comprehensive income/(loss)(3,224)(3,099)
Total Thermo Fisher Scientific Inc. shareholders’ equity46,73543,978
Noncontrolling interests(11)54
Total equity46,72444,032
Total liabilities, redeemable noncontrolling interest and equity$ 98,726$ 97,154
TMO
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEthermofisher.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES65535

Thermo Fisher Scientific Inc Frequently Asked Questions


What is the ticker symbol for Thermo Fisher Scientific Inc? What does TMO stand for in stocks?

TMO is the stock ticker symbol of Thermo Fisher Scientific Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Thermo Fisher Scientific Inc (TMO)?

As of Fri Apr 19 2024, market cap of Thermo Fisher Scientific Inc is 207.81 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TMO stock?

You can check TMO's fair value in chart for subscribers.

What is the fair value of TMO stock?

You can check TMO's fair value in chart for subscribers. The fair value of Thermo Fisher Scientific Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Thermo Fisher Scientific Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TMO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Thermo Fisher Scientific Inc a good stock to buy?

The fair value guage provides a quick view whether TMO is over valued or under valued. Whether Thermo Fisher Scientific Inc is cheap or expensive depends on the assumptions which impact Thermo Fisher Scientific Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TMO.

What is Thermo Fisher Scientific Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, TMO's PE ratio (Price to Earnings) is 34.9 and Price to Sales (PS) ratio is 4.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Thermo Fisher Scientific Inc's stock?

In the past 10 years, Thermo Fisher Scientific Inc has provided 0.166 (multiply by 100 for percentage) rate of return.